Brivaracetam
- Generic Name
- Brivaracetam
- Brand Names
- Briviact, Briviact (in Italy: Nubriveo)
- Drug Type
- Small Molecule
- Chemical Formula
- C11H20N2O2
- CAS Number
- 357336-20-0
- Unique Ingredient Identifier
- U863JGG2IA
- Background
Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam . It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 .
- Indication
Used as adjunctive therapy for partial-onset seizures in patients 16 years of age or older.
- Associated Conditions
- Partial-Onset Seizures
- Associated Therapies
- -
Compassionate Use Program With Brivaracetam for the Treatment of Patients With Epilepsy
- Conditions
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- UCB Biopharma SRL
- Registration Number
- NCT03532516
Brivaracetam: a Prospective and Multicentre Post-marketing Observational Study
- Conditions
- First Posted Date
- 2018-05-07
- Last Posted Date
- 2023-12-19
- Target Recruit Count
- 51
- Registration Number
- NCT03517423
- Locations
- 🇨🇦
Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec, Canada
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- UCB Biopharma S.P.R.L.
- Target Recruit Count
- 50
- Registration Number
- NCT03405714
- Locations
- 🇭🇺
Ep0065 210, Budapest, Hungary
🇭🇺Ep0065 247, Budapest, Hungary
🇨🇿Ep0065 502, Hradec Králové, Czechia
A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
- Conditions
- Interventions
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 217
- Registration Number
- NCT03250377
- Locations
- 🇨🇳
Ep0085 905, Beijing, China
🇨🇳Ep0085 901, Chengdu, China
🇨🇳Ep0085 902, Guangzhou, China
A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy
- Conditions
- Interventions
- First Posted Date
- 2017-03-20
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 449
- Registration Number
- NCT03083665
- Locations
- 🇨🇳
Ep0083 902, Guangzhou, China
🇨🇳Ep0083 912, Hangzhou, China
🇨🇳Ep0083 910, Shijiazhuang, China
A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- UCB Biopharma S.P.R.L.
- Target Recruit Count
- 46
- Registration Number
- NCT03021018
- Locations
- 🇺🇸
Ep0087 108, Birmingham, Alabama, United States
🇺🇸Ep0087 117, Tucson, Arizona, United States
🇺🇸Ep0087 112, Orlando, Florida, United States
A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2017-10-30
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 13
- Registration Number
- NCT02602860
- Locations
- 🇺🇸
Ep0074 001, New Haven, Connecticut, United States
Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy
- First Posted Date
- 2012-11-16
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 26
- Registration Number
- NCT01728077
- Locations
- 🇺🇸
108, Lexington, Kentucky, United States
🇺🇸110, Dallas, Texas, United States
🇺🇸103, Little Rock, Arkansas, United States
A Study to Investigate the Drug-Drug Interactions of Brivaracetam and Ethanol in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2012-10-19
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 18
- Registration Number
- NCT01710670
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
- First Posted Date
- 2012-07-30
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 29
- Registration Number
- NCT01653262
- Locations
- 🇺🇸
108, Lexington, Kentucky, United States
🇺🇸103, Little Rock, Arkansas, United States
🇺🇸109, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.